CSG's €18 Billion Order Book Faces a €695 Million Cash Drain

CSG's pitch to investors has long rested on a simple proposition: a record order book and rising European defence budgets would eventually translate into hard earnings. JPMorgan's latest assessment throws a wrench into that narrative, and the market's reaction was swift. The stock fell 7.6% on the day the U.S. bank cut its rating from "Overweight" to "Neutral" and slashed its price target to €12 from €27.50 — a revision that speaks volumes about how sharply the earnings outlook has been reined in.

At the heart of the downgrade is a financing gap that JPMorgan now expects to define 2026. The bank projects free cash flow of minus €695 million for the year, a stark reversal from its previous forecast of plus €860 million. Higher working capital requirements and loans extended to suppliers are cited among the drivers. Analyst David Perry also flagged margin risks in medium- and large-calibre ammunition, weaker cash flow expectations and the burden of supplier financing — all of which push questions about the financial quality of the business to the fore.

The Working Capital Target That Moved

CSG itself provided the clearest signal that capital intensity is climbing. On the day before the downgrade, the company raised its expected net working capital ratio for year-end to below 35% of revenue, up from a prior target of below 20%. That shift permits significantly more capital to be tied up in the operating business relative to sales — money that is not immediately available for other purposes.

The company's revenue guidance for 2026 was left untouched at €7.4 billion to €7.6 billion. Investors therefore face two expectations simultaneously: CSG is holding firm on its top-line target while budgeting for a much heavier working capital load. How that combination affects financial headroom is now the central question.

Should investors sell immediately? Or is it worth buying CSG?

Management offered some reassurance during yesterday's earnings call, indicating a normalisation in the coming year. That would mark meaningful progress — provided CSG actually releases the tied-up funds. For judging the equity, that execution arguably matters more than another record backlog headline.

Supplier Support Cuts Both Ways

The cost of the transition is visible in the support CSG is extending to its supply chain. The company granted suppliers €700 million in bridge financing to fund capacity expansion. In the first nine months of 2026, free cash flow came in at minus €777 million.

Such financing can underpin the industrial build-out, so long as the needed capacity materialises. For shareholders, though, it represents an added burden: CSG is bankrolling part of the industrial groundwork for its own growth. Success therefore depends on execution beyond its own factory gates.

The demand backdrop is shifting too. Perry sees risks for medium- and large-calibre ammunition from drone deployment and customers gravitating toward greater range. CSG must overhaul its production while simultaneously making its supply chain more capable — a strategic direction that makes sense only if economically viable deliveries follow in time.

A Backlog Worth Dissecting

The order book stood at €18 billion at the end of September, a record. But its composition deserves scrutiny: €7 billion in firm orders and €8 billion in framework agreements, with less binding orders making up the remainder. Firm bookings give CSG a more reliable basis for production planning, while framework contracts only take economic effect as actual call-offs materialise.

Revenue for the first nine months of 2026 reached €4.76 billion, 6.1% above the prior-year level. The bullish case leans on this combination — orders in hand and a revenue target intact. Should profitability stabilise alongside, confidence in earnings power could return. The prerequisite remains economically sound execution.

The production shift is already well advanced. In the third quarter of 2026, nearly all of CSG's own 155-mm output was long-range ammunition, up from roughly 35% in the first half. That aligns with the demand shift Perry describes, yet selling cheaper standard munitions is weighing on margins. CSG called the pressure transitory on yesterday's call but acknowledged possible drag in the coming year as well.

Margins Take the Hit

The profitability picture darkened yesterday when CSG cut its expected operating EBIT margin for 2026 to approximately 21%, down from 24–25%. Management cited price-reduced sales of standard-range ammunition and the lower-margin ramp-up in Land Systems.

Third-quarter figures illustrate the strain: revenue fell 11.7% to €1,510 million, while operating EBIT declined 20.9%. The gap between the two declines underscores why earnings stabilisation has become pivotal. A more favourable valuation would require CSG to demonstrate that the sharper drop in operating profit can be contained.

CSG at a turning point? This analysis reveals what investors need to know now.

The bear case envisions these pressures persisting. If price concessions remain necessary and ramp-up costs keep eating into returns, revenue will contribute less to financial relief. The most demanding combination would be weaker margins paired with persistently high capital binding — conditions under which the financing questions raised by JPMorgan would carry added weight.

What the Long Game Requires

CSG aims to complete vertical integration of long-range ammunition by the end of 2027. In-house production of explosives and propellant powder is expected to contribute to a margin of 26–28% over the medium term. That is the industrial opportunity: greater value capture can improve profitability, if the build-out succeeds and demand keeps capacity utilised. Perry's warning about price pressure from additional industry capacity attaches a clear condition to that hope.

A planned dividend starting in 2027, paid out of the 2026 financial year's profit, remains on the table according to CSG — though its size explicitly depends on earnings and cash flow.

The next concrete checkpoint is the year-end net working capital figure. Credible data there would show how well CSG is meeting its revised targets. A more durable recovery case needs better margins and controlled capital binding to arrive together. Until then, the viability of the business model under its altered earnings and financing assumptions stays front and centre for investors — and the gap between the order book and the bottom line is where the story will be settled.

Ad

CSG Stock: New Analysis - 13 November

Fresh CSG information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated CSG analysis...